Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 1127Neoplasms 982Carcinoma, Non-Small-Cell Lung 900Prostatic Neoplasms 594Neoplasm Metastasis 528Leukemia, Myeloid, Acute 513Colorectal Neoplasms 491Lung Neoplasms 487Melanoma 485Multiple Myeloma 477Pancreatic Neoplasms 385Lymphoma 369Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 346Leukemia 339Leukemia, Lymphocytic, Chronic, B-Cell 321Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 273Carcinoma, Hepatocellular 261Glioblastoma 249Lymphoma, Large B-Cell, Diffuse 244Myelodysplastic Syndromes 242Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

TIC10 compound 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Endometrial Cancer Recurrent × Clear all
NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

National Cheng-Kung University Hospital

Phase 2 Terminated
40 enrolled
Gynecologic

Endometrial Cancer Recurrent

NCT03485729 2024-12-24

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Jazz Pharmaceuticals

Phase 2 Terminated
27 enrolled 11 charts
Gynecologic

Endometrial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡